Universal Ibogaine Inc. (IBO.V)
CAD 0.03
(0.0%)
CAD 0.03
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2022 | -10.49 Million CAD | -171.41% |
| 2021 | -3.86 Million CAD | -3168.74% |
| 2020 | -118.3 Thousand CAD | -20.59% |
| 2019 | -98.1 Thousand CAD | 75.97% |
| 2018 | -408.28 Thousand CAD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 Q3 | -486.59 Thousand CAD | 38.63% |
| 2023 Q2 | -792.85 Thousand CAD | 5.83% |
| 2023 Q1 | -841.96 Thousand CAD | 87.15% |
| 2022 Q1 | -1.73 Million CAD | -7373.61% |
| 2022 FY | -10.49 Million CAD | -171.41% |
| 2022 Q4 | -6.55 Million CAD | -458.21% |
| 2022 Q3 | -1.17 Million CAD | -12.87% |
| 2022 Q2 | -1.03 Million CAD | 39.93% |
| 2021 Q4 | -23.16 Thousand CAD | 72.23% |
| 2021 Q2 | -83.08 Thousand CAD | -19.4% |
| 2021 Q3 | -83.42 Thousand CAD | -0.41% |
| 2021 FY | -3.86 Million CAD | -3168.74% |
| 2021 Q1 | -69.58 Thousand CAD | -27.54% |
| 2020 FY | -118.3 Thousand CAD | -20.59% |
| 2020 Q4 | -54.55 Thousand CAD | -53.62% |
| 2020 Q3 | -35.51 Thousand CAD | -60.28% |
| 2020 Q2 | -22.15 Thousand CAD | 28.11% |
| 2020 Q1 | -30.82 Thousand CAD | -3.36% |
| 2019 Q1 | -18.39 Thousand CAD | 46.05% |
| 2019 FY | -98.1 Thousand CAD | 75.97% |
| 2019 Q4 | -29.81 Thousand CAD | -63.84% |
| 2019 Q3 | -18.19 Thousand CAD | 33.64% |
| 2019 Q2 | -27.42 Thousand CAD | -49.09% |
| 2018 FY | -408.28 Thousand CAD | 0.0% |
| 2018 Q4 | -34.09 Thousand CAD | 4.68% |
| 2018 Q3 | -35.76 Thousand CAD | 63.67% |
| 2018 Q1 | -177.61 Thousand CAD | -84.11% |
| 2018 Q2 | -98.44 Thousand CAD | 44.58% |
| 2017 Q4 | -96.47 Thousand CAD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Arch Biopartners Inc. | -3.32 Million CAD | -215.511% |
| Covalon Technologies Ltd. | -4.46 Million CAD | -135.288% |
| Hemostemix Inc. | -2.5 Million CAD | -319.494% |
| Kane Biotech Inc. | -5.03 Million CAD | -108.502% |
| MedMira Inc. | -2.67 Million CAD | -292.285% |
| Marvel Biosciences Corp. | -2.29 Million CAD | -358.072% |
| NervGen Pharma Corp. | -22.38 Million CAD | 53.105% |
| XORTX Therapeutics Inc. | -2.85 Million CAD | -267.081% |